| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology and Kaplan Comprehensive Cancer
Center,*
New York University School of Medicine, New York,
New York; and the Department of Pediatrics,
Memorial Sloan-Kettering Cancer Center, New York, New York
Human neuroblastoma cell lines typically consist of heterogenous subpopulations of cells that are morphologically and biochemically distinct. The cell types are characterized as neuroblastic (N-type), substrate-adherent Schwann-like (S-type), or intermediate (I). These cell types can undergo spontaneous or induced transdifferentiation in vitro. We investigated the complement sensitivity of different neuroblastoma cell lines and of matched sets of cloned N- and S-type neuroblastoma cell lines. Human neuroblastoma cell lines that consisted predominantly of a neuroblastic phenotype were shown to be significantly more susceptible to human complement-mediated lysis than cell lines of other cancer types. Complement sensitivity of neuroblastoma cell lines was correlated with low levels of CD59, decay-accelerating factor, and membrane cofactor protein expression. We found that cloned S-type neuroblastoma cells were much more resistant to complement-mediated lysis than cloned N-type cells. The increased complement resistance of S-type cells was shown to be due to increased expression of membrane-bound complement inhibitors. CD59 was the single most important protein in providing S-type cells with protection from complement lysis. S-type cells were also found to express lower levels of GD2, a target antigen for a complement activating monoclonal antibody currently in clinical trials for neuroblastoma immunotherapy. The ability of S-type cells to evade complement, and the ability of S-type cells to differentiate into the more tumorigenic N-type cells, may represent a mechanism of tumor survival and regrowth, a phenomenon often observed with this cancer.
This article has been cited by other articles:
 |
|
 |
|
  J. van Beek, M. van Meurs, B. A. 't Hart, H. P. M. Brok, J. W. Neal, A. Chatagner, C. L. Harris, N. Omidvar, B. P. Morgan, J. D. Laman, et al. Decay-Accelerating Factor (CD55) Is Expressed by Neurons in Response to Chronic but Not Acute Autoimmune Central Nervous System Inflammation Associated with Complement Activation J. Immunol., February 15, 2005; 174(4): 2353 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K A Gelderman, H J M A A Zijlmans, M J Vonk, and A Gorter CD55 expression patterns on intestinal neuronal tissue are divergent from the brain Gut, April 1, 2004; 53(4): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bian, T. D. Giordano, H.-J. Lin, G. Solomon, V. P. Castle, and A. W. Opipari Jr. Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation J. Biol. Chem., February 6, 2004; 279(6): 4663 - 4669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Y. Cheung, M. S. Lo Piccolo, B. H. Kushner, K. Kramer, and N.-K. V. Cheung Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma J. Clin. Oncol., March 15, 2003; 21(6): 1087 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Bian, A. W. Opipari Jr., A. B. Ratanaproeksa, A. E. Boitano, P. C. Lucas, and V. P. Castle Constitutively Active NFkappa B Is Required for the Survival of S-type Neuroblastoma J. Biol. Chem., October 25, 2002; 277(44): 42144 - 42150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zatyka, N. F. da Silva, S. C. Clifford, M. R. Morris, M. S. Wiesener, K.-U. Eckardt, R. S. Houlston, F. M. Richards, F. Latif, and E. R. Maher Identification of Cyclin D1 and Other Novel Targets for the von Hippel-Lindau Tumor Suppressor Gene by Expression Array Analysis and Investigation of Cyclin D1 Genotype as a Modifier in von Hippel-Lindau Disease Cancer Res., July 1, 2002; 62(13): 3803 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mora, N.-K. V. Cheung, G. Juan, P. Illei, I. Cheung, M. Akram, S. Chi, M. Ladanyi, C. Cordon-Cardo, and W. L. Gerald Neuroblastic and Schwannian Stromal Cells of Neuroblastoma Are Derived from a Tumoral Progenitor Cell Cancer Res., September 1, 2001; 61(18): 6892 - 6898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen, T. Caragine, N.-K. V. Cheung, and S. Tomlinson CD59 Expressed on a Tumor Cell Surface Modulates Decay-accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma Cancer Res., June 1, 2000; 60(11): 3013 - 3018. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
